back to top
3.31.2020 – 5.1.2020


Obdulio Piloto b.1978
These abstract works were made sporadically by Dr. Piloto inside his Miami laboratory between the challenging moments of persuing something thought to be impossible. The artist sought not only to have the scope to fully explore materials, color, medium, and texture but also to hide deeper meaning using a variety of materials. They have absorbed the tension between the unrestrained, self-taught artist, the highly trained scientist, and the curious inventor…often times hiding under plain sight thoughts that keep him up at night.
Mediums used
DNA encrypted paint, candles, acetones, psyllium husk, dyes, clay, fire, water, carbon nanoparticles, gold, and 12 carats of ethically mined diamonds.
+ also available on Virtual Reality

Obdulio Piloto B. 1978 - Cuban-American.

Dr. Obdulio Piloto improves his scientific creativity through artistic practice. He acknowledges creativity is transformative and central to scientific pursuits. As a radical scientist and social entrepreneur, his ambitions rely on challenging ineffective healthcare systems, specially in the early diagnosis of diseases like cancer. His global team is developing novel biomedical approaches, and cross-pollinating disciplines like nanotechnology, organic chemistry, materials science, molecular medicine and artificial intelligence. As an American-born, descendant of Cuban immigrants, Cuban Slang written using spray paint, often play a role in transmitting, highly complex themes. He often acknowledges his introvertedness and reclusiveness as an impediment for greater social change. As an artist, his greatest contribution to art history could be pioneering the Molecular Portrait; artworks depicting people as deconstructed mixtures of molecules, an avant-garde series of work that reimagine our entire humanity. As certain symbols have become “visual code,” allowing people from vastly different cultures and generations, to comprehend each others, he hopes Molecular Portraiture remove our human-derived preconceptions about others while probing the vulnerabilities of the existential human condition. Through this visual language, he explores human identity and its essence as automation, CRISPR, AI, and wealth inequality take shape in our society.  He often creates a dialogue between the technological and ideological differences between the East and West and their race for supremacy.
Dr. Piloto revisits the influence of science and history, and creates parallels that challenge new forms of exploring the past, when imagining the future.
At a time when understanding our interconnectedness and fragility is most critical, the radical notion of “Molecular Portraits” provides a unique perspective that he hopes, at the very least, helps us better understand what makes us human.
The “dots” if proven successful, will greatly contribute to the future of our species.
His invention is currently under clinical human trials in China.
Dr. Piloto works with Peter Thiel’s Breakout Labs, Singapore’s Temasek Laboratory, and Bill Gate’s Global Good.


-Cornell University – B.S. Biological Sciences (microbiology)
-Johns Hopkins University School of Medicine – Ph.D. Cellular and Molecular Medicine
-Stanford University School of Medicine – Post Doctoral Fellow
1995- Westinghouse Science Competition
1996-2000- Dean’s List, Cornell University
1998-2000- Ho-Nun-De-Kah Honor Society, Cornell University
2000- Cum laude, Cornell University
2000- Distinction in Research, Cornell University
2006-2007- National Cancer Institute, Cancer Biology Fellowship
2007- American Cancer Society Fellowship
2012- Peter Thiel Foundation Breakout Labs, funding for Entopsis
2014- Awesome Foundation Miami, micro-grant
2016-  Disruptive Technology Award (Entopsis), Greater Miami Chamber of Commerce
1. Piloto O, Cheong I, et. al. “Method and Device for verification of urine”
2. Piloto O, Cheong I, “Detectable Arrays, Systems for Diagnosis, and Methods of Making and Using the Same”
3. Piloto O, Cheong I, Sjöblom T. “A novel statistical algorithm for pattern classification and recognition”
1. Sum R, Swaminathan M, Rastogi SK, Piloto O and Cheong I. Beta-hemolytic bacteria selectively trigger liposome lysis, enabling rapid and accurate pathogen detection. ACS Sensors (accepted), 2017.
2. Swaminathan M, Yadav PK, Piloto O, Sjöblom T, and Cheong I. Use of a new Poisson-Binomial semi-metric for Image Classification and Recognition. Pattern Recognition, 63: 384–396, 2016
3. Matheny CJ, Wei MC, Bassik MC, Donnelly AJ, Kampmann M, Iwasaki M, Piloto O, Solow-Cordero DE, Bouley DM, Rau R, Brown P, McManus MT, Weissman JS, and Cleary ML. Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. Cell: Chemistry & Biology 20, 1–12, 2013.
4. Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, Levis M, Small D. Further Activation of FLT3 Mutants by FLT3 Ligand. Oncogene 30(38), 4004-4014, 2011.
5. Wang Z, Sommervaille T, Murphy MJ, Piloto O, Smith K and Cleary ML. Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy. Nature, 455(7217): 1205-1209, 2008.
6. Li L, Piloto O, Nguyen B, Greenberg K, Takamiya K, Racke F, Huso D, Sun L, Small D. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood, 111(7): 3849-3858, 2008.
7. Kim K, Baird K, Davis S, Levis M, Piloto O, Li L, Chen P, Meltzer P, Small D. Constitutive FLT3 activation results in specific changes in gene expression in myeloid leukemic cells. Br J Haematol. 138(5): 603-615, 2007.
8. Li L, Piloto O, Ye Z, Kim K, Nguyen B, Yu X, Levis M, Cheng L, Small D. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human hematopoietic stem/progenitor cells. Br J Haematol. 137 (1): 64-75, 2007.
9. Piloto O, Wright M, Brown P, Kim K, Levis M, Small D. Prolonged Exposure to FLT3 Inhibitors leads to Resistance via Activation of Parallel Signaling Pathways. Blood 109(4): 1643-1652, 2007.
10. Piloto O, Nguyen B, Huso D, Kim K, Li Y, Witte L, Hicklin DJ, Brown P, Small D. EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces NOD/SCID engraftment of some ALL cell lines and primary blasts. Cancer Research 66(9): 4843-4851, 2006.
11. Piloto O, Levis M, Huso D, Li Y, Li H, Wang M, Lu D, Wu Y, Bassi R, Balderes P, Zhang H, Ludwig DL, Pytowski B, Kussie P, Bohlen P, Witte L, Zhu Z, Hicklin DJ, Small D.   Inhibitory anti-FLT3 mAb are capable of mediating ADCC and reducing engraftment of AML blasts in NOD/SCID mice without reducing engraftment of normal hematopoietic stem cells. Cancer Research 65(4): 1514-1522, 2005.
12. Zheng R, Levis M, Piloto O, Brown P, Baldwin B, Gorin N, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 103(1): 267-274, 2004.
13. Li Y, Li H, Wang M, Lu D, Wu Y, Bassi R, Balderes P, Zhang H, Ludwig DL, Pytowski B, Kussie P, Piloto O, Small D, Bohlen P, Witte L, Zhu Z, Hicklin DJ. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood 104(4): 1137-1144, 2004.
es_ESEspañol en_USEnglish